title: Long-term adverse effects of cyclophosphamide on follicular growth and angiogenesis in mouse ovaries.
abstract: The adverse effects of the anti-cancer agent cyclophosphamide (CTX) on follicular growth and ovarian angiogenesis were investigated in mice. CTX treatment irreversibly induced a loss of follicles through apoptosis and decreased microvascularization of the corpora lutea and follicles in a dose-dependent manner. Our findings demonstrated that CTX adversely affected the ovaries indicating the need to support an awareness of fertility preservation before chemotherapy is initiated.
authors.affiliation: Kato Ladies Clinic, 7-20-3 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Ezoe
authors.affiliation: Kato Ladies Clinic, 7-20-3 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.
authors.forename: Nana
authors.initials: N
authors.lastname: Murata
authors.affiliation: Kato Ladies Clinic, 7-20-3 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan. Electronic address: a-yabuuchi@towako-kato.com.
authors.forename: Akiko
authors.initials: A
authors.lastname: Yabuuchi
authors.affiliation: Kato Ladies Clinic, 7-20-3 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Okuno
authors.affiliation: Kato Ladies Clinic, 7-20-3 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.
authors.forename: Tamotsu
authors.initials: T
authors.lastname: Kobayashi
authors.affiliation: Kato Ladies Clinic, 7-20-3 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.
authors.forename: Osamu
authors.initials: O
authors.lastname: Kato
authors.affiliation: Kato Ladies Clinic, 7-20-3 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan. Electronic address: k-kato@towako.net.
authors.forename: Keiichi
authors.initials: K
authors.lastname: Kato
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects*; D017209:Apoptosis / Q000187:drug effects; D003338:Corpus Luteum / Q000098:blood supply / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects*; D004249:DNA Damage; D004305:Dose-Response Relationship, Drug; D005260:Female; D018507:Gene Expression Regulation, Developmental / Q000187:drug effects; D007150:Immunohistochemistry; D007274:Injections, Intraperitoneal; D008810:Mice, Inbred C57BL; D055806:Microvessels / Q000187:drug effects / Q000254:growth & development; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D009866:Oogenesis / Q000187:drug effects*; D006080:Ovarian Follicle / Q000166:cytology / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism; D010053:Ovary / Q000098:blood supply / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism; D011897:Random Allocation; D013997:Time Factors
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide
keywords: Angiogenesis; Corpus luteum; Cyclophosphamide; Follicular growth